ArticleDevelopment (Cambridge, England)2020
Targeted cell ablation in zebrafish using optogenetic transcriptional control.
Article in Development (Cambridge, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- An optogenetic toolkit for robust activation of FGF, BMP, & Nodal signaling in zebrafish.Developmental biology · 2026Article
- Light-inducible FLPase reconstitution enables temporal control of gene expression in Drosophila melanogaster.Cell reports methods · 2026Article
- Tunable gene expression in zebrafish using RiboSCALE.bioRxiv : the preprint server for biology · 2026Article
- Effects of age on the response to spinal cord injury: optimizing the larval zebrafish model.Developmental biology · 2025Article
- Review
- Full-field exposure of larval zebrafish to narrow waveband LED light sources at defined power and energy for optogenetic applications.Journal of neuroscience methods · 2024Article
- Optogenetic Signaling Activation in Zebrafish Embryos.Journal of visualized experiments : JoVE · 2023Article
- OPTO-BLUE: An Integrated Bidirectional Optogenetic Lentiviral Platform for Controlled Light-Induced Gene Expression.International journal of molecular sciences · 2023Article
- Review
- Precise modulation of embryonic development through optogenetics.Genesis (New York, N.Y. : 2000) · 2022Review
- The Development and Application of Opto-Chemical Tools in the Zebrafish.Molecules (Basel, Switzerland) · 2022Review
- Zebrafish: an underutilized tool for discovery in host-microbe interactions.Trends in immunology · 2022Review
- Rapid and robust optogenetic control of gene expression in Drosophila.Developmental cell · 2021Article
- Review
- Article
- Insights Into Central Nervous System Glial Cell Formation and Function From Zebrafish.Frontiers in cell and developmental biology · 2021Review
- Non-neuromodulatory Optogenetic Tools in Zebrafish.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cell ablation is a powerful method for elucidating the contributions of individual cell populations to embryonic development and tissue regeneration. Targeted cell loss in whole organisms has been typically achieved through expression of a cytotoxic or prodrug-activating gene product in the cell type of interest. This approach depends on the availability of tissue-specific promoters, and it does not allow further spatial selectivity within the promoter-defined region(s). To address this limitation, we have used the light-inducible GAVPO transactivator in combination with two genetically encoded cell-ablation technologies: the nitroreductase/nitrofuran system and a cytotoxic variant of the M2 ion channel. Our studies establish ablative methods that provide the tissue specificity afforded by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.